Cathie Wood’s ARK buys Robinhood stock, sells Bitcoin ETF

ARK disclosed a mixed set of daily trades on April 29, 2026, highlighted by a $45.5 million purchase of 553,892 Robinhood shares and a $31.8 million purchase of 2.41 million Intellia shares. It also added $11.8 million of Kratos while trimming exposure to the ARK 21Shares Bitcoin ETF by 243,147 shares and selling 63,000 Twist Bioscience shares. The activity signals continued rotation toward fintech, biotech, and defense, while reducing crypto exposure.

Analysis

The important signal is not the individual tickets, but the clustering: ARK is adding to high-beta names where incremental flow can still move the tape, which tends to matter more for sentiment than fundamentals in the next 1-4 weeks. That creates a reflexive setup in HOOD and KTOS: both can benefit from visible sponsor demand because they already screen as retail-friendly momentum vehicles, while NTLA gets an extra layer of support from positioning in a sector where capital is scarce and follow-on financings remain a key overhang.

The second-order effect is that this is a relative-value event, not a broad risk-on signal. ARK rotating out of crypto exposure while adding fintech and biotech suggests a preference for names with more idiosyncratic catalysts and less direct beta to the highest-volatility macro factor. That is mildly negative for crypto-adjacent liquidity proxies in the near term, but more importantly it can keep a lid on TWST by reinforcing the market’s suspicion that the genomics basket still lacks a clean commercialization path.

For HOOD, the near-term risk is that the trade becomes crowded into the next earnings window; if user engagement or options activity softens, the stock can mean-revert quickly because the valuation already prices in sustained retail activity. NTLA is the highest convexity name here: positive flow can support the shares for days to weeks, but the real swing factor is whether the market believes upcoming data derisks the platform enough to justify financing dilution risk over the next 6-12 months. KTOS looks like the cleanest momentum continuation, but defense multiples can compress fast if broader small-cap growth sentiment weakens.

The contrarian read is that ARK may be buying strength rather than edge: these are the kinds of names that work best when sponsor flow is scarce, but the market has now learned to front-run ARK. That means the better trade may be to fade post-purchase strength in the most crowded name and own the one with the most credible fundamental catalyst. TWST remains the weakest tape participant because selling into a biotech support rotation often indicates capital is being reallocated away from lower-confidence platform stories.

Key Decisions for Investors

• Long HOOD for 1-3 weeks on pullbacks only; use sponsor-flow support into earnings momentum, but size modestly because the upside is likely 8-12% while downside on any activity miss can be 10-15%.
• Long KTOS vs short XAR or IWM for 1-2 months; defense-specific order flow plus ARK sponsorship gives KTOS a cleaner relative-strength setup than the broader small-cap complex.
• Small tactical long NTLA for 2-6 weeks as a flow/positioning trade, but pair it against a biotech index or basket short to isolate idiosyncratic upside while limiting sector beta; keep tight risk because dilution headlines can reverse the move quickly.
• Fade TWST on strength over the next several sessions; sell-rallies or structure a short against a stronger genomics peer, as the repeated selling suggests the market is signaling lower conviction in the business quality.
• Avoid chasing ARKB weakness as a standalone short; use it only as a hedge against crypto-beta exposure since the trade looks more like capital rotation than a durable bearish view on digital assets.